Margaret Hemmen in Austin, Texas

Medical School: Sorry, her university is not listed
Graduation Year: 2011
The Primary Medical Specialty for Margaret Hemmen is listed as: Nurse Practitioner
Approximate Years of Experience: 13
PAC (PECOS ID)#: 1052564259
NPI #: 1285909739
NPI Created On: 03/16/2012
NPI Last Updated Listed as: 04/22/2021
Primary Taxonomy Code: 363LF0000X
License Number:
723147
Listed Gender: Female

Forms of insurance accepted by include, but are not limited to:

• Celtic Insurance Company
• Humana
• Oscar Insurance Company
• Blue Cross Blue Shield
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.

Services and Procedures include:

1. Blood test, comprehensive group of blood chemicals
2. Blood test, lipids (cholesterol and triglycerides)
3. Blood glucose (sugar) level
4. Hemoglobin a1c level
5. Blood test, thyroid stimulating hormone (tsh)
6. Vaccine for influenza for injection into muscle
7. Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older
8. Established patient office or other outpatient visit, typically 10 minutes
9. Established patient office or other outpatient visit, typically 15 minutes
10. Established patient office or other outpatient, visit typically 25 minutes
11. Administration of influenza virus vaccine
12. Administration of pneumococcal vaccine
13. Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment
14. Electrocardiogram, routine ecg with 12 leads; performed as a screening for the initial preventive physical examination with interpretation and report
15. Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit
16. Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit
17. Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r